Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib plus high-dose cytarabine and mitoxantrone in relapsed/refractory FLT3-ITD AML (Q-HAM)
2018-002675-17Phase 2Terminated
- Sponsor
- Heidelberg University Faculty of Medicine
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quizartinib in acute myeloid leukemia (AML), sponsored by Heidelberg University Faculty of Medicine. Primary endpoint: CR/CRi rate. Started Aug 2019; status: terminated.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002675-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002675-17.